Henderson, Nevada Jan 8, 2023 (Issuewire.com) – CORSTASIS THERAPEUTICS Presenting at BIOTECH SHOWCASE 2023
Corstasis Therapeutics, Inc. (“Corstasis”), a clinical-stage pharmaceutical company focused on advancing outpatient options for patients suffering from Edema, announced today that Ben Esque, Chief Executive Officer, will present a corporate and clinical overview at 10:30 a.m. PT on Wednesday, January 11, 2023, at BIOTECH SHOWCASE (Hilton San Francisco Union Square, Yosemite C, Ballroom Level). Registered attendees may attend the presentation in person or view it through the BIOTECH SHOWCASE webcast platform. Corstasis will be available for one-on-one investor meetings at the conference, which can be requested via the BIOTECH SHOWCASE booking platform.
“We are excited to share our story at BIOTECH SHOWCASE. We are confident our products will deliver valuable options for healthcare providers to treat patients outside of the hospital. Science demonstrates that keeping patients out of the hospital not only improves patient outcomes but also reduces the overall cost of care. Our programs have been intentionally designed to minimize regulatory risk while delivering maximum clinical value.” added Esque.
Corstasis will be providing details about its lead clinical program RSQ-777, the target patient population, and the market potential of the company.
“We are delighted that Corstasis Therapeutics will be joining us in San Francisco and presenting at BIOTECH SHOWCASE this year,” said Sara Demy, CEO of Demy-Colton, “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
BIOTECH SHOWCASE, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Those interested in registering for Biotech Showcase may do so using the link, here.
ABOUT CORSTASIS THERAPEUTICS
Corstasis Therapeutics is a clinical-stage pharmaceutical company focused on advancing outpatient options for patients suffering from fluid overload (Edema) associated with congestive heart failure (CHF) and liver & kidney disease. Corstasis Therapeutics lead product candidate is clinical-stage RSQ-777, an intranasal diuretic product that leverages a novel formulation of a proven therapeutic agent (with roughly 40 years of safety and efficacy data) and the Aptar Uni Dose Delivery System which is currently used with multiple FDA approved therapies. Additional information can be found at www.corstasis.com.
Benjamin Esque, 702-541-9222, [email protected]
Biotech Showcase: @EBDGroup – @Demy_Colton – #BiotechShowcase
Source :Corstasis Therapeutics
This article was originally published by IssueWire. Read the original article here.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Smart Herald journalist was involved in the writing and production of this article.